Galapagos rises on FDA clearance for phase 1/2 ATALANTA-1 study

Lakefront Biotherapeutics NV

23/08/2024 08:32

** Shares in Galapagos  GLPG.AS  rise 2.7%, paring earlier
gains of as much as 4%, after the Belgian biotech company
obtained FDA clearance to initiate its ATALANTA-1 study with
GLPG5101 in the U.S.
    ** "We see the FDA clearance as an important milestone for
Galapagos' GLPG5101 program," says KBC Securities, adding the
company will now be able to start treating patients in the U.S.
through their decentralized manufacturing platform
    ** "Point-of-care manufacturing appears feasible," says Van
Lanschot Kempen, adding the median 7 days vein-to-vein time for
GLPG5101 is faster than competitors
    ** "We believe that inclusion of additional manufacturing
sites in the U.S. is required to make more meaningful
conclusions regarding the feasibility of decentralized CAR T
manufacturing," it notes
    ** Friday's rise pares the stock's YTD losses to about
37.8%​

 (Reporting by Dimitri Rhodes)
 ((Dimitri.Rhodes@thomsonreuters.com;))